Lumida
/INNV
⌘K
InnovAge Holding Corp

InnovAge Holding Corp

INNV
$11.50USD-3.12%-0.37 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

37.6x

DAY RANGE

$11 – $12

52W RANGE

$3
$13

AI Summary

Stalk
StalkMedium

INNV remains in a Stage 2 advancing uptrend with a recent Momentum Breakout confirming fresh demand, but price is extended far above rising EMAs with extreme overbought conditions. Medium-term bias stays bullish, yet near-term timing is unfavorable. Defer execution and wait for a pullback into the 9/21 EMA zone or the prior resistance-turned-support area for optimal entry.

  • Q3 revenue of $252M (+15.5% YoY) driven by higher capitation rates
  • Adjusted EBITDA margin rose to 12.1%, up 730bps on operational efficiencies
  • Q3 net loss of $29.9M underscores profitability challenges
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

InnovAge Holdings, Inc. (NASDAQ: INNV) is a leading provider of comprehensive healthcare services for seniors through its PACE (Program of All-Inclusive Care for the Elderly) model. As the largest provider in the PACE space, InnovAge aims to enhance the quality of life for seniors by delivering integrated healthcare management designed to keep participants within their communities while fulfilling their complex healthcare needs. The company operates in a highly regulated environment, making it essential to navigate various policy changes effectively.

Bull says

  • Q3 revenue of $252M (+15.5% YoY) driven by higher capitation rates
  • Adjusted EBITDA margin rose to 12.1%, up 730bps on operational efficiencies
  • Member census reached 8,050 (+6.9% YoY) via re-engagement initiatives
  • Piloting AI tools to enhance care coordination and drive efficiency
  • FY26 revenue guidance raised to $950M–$975M reflecting strong momentum
  • High earnings yield, strong momentum and quality metrics, low leverage risk

Bear says

  • Q3 net loss of $29.9M underscores profitability challenges
  • Liquidity constrained with limited trading, hindering price discovery
  • FY27 Medicaid rate increases likely lower, posing revenue headwinds
  • G&A expenses surged 98.3% on litigation liabilities, pressuring margins
  • Weak profitability and dividend factors signal sustainability concerns
  • Rising state budget pressures may further strain service margins

Investment themes with INNV

Demographics: Elderly Care +0.43%

Services and products for aging population

ENSG · ACHC · SEM

Earnings Call · Q3 2026 · Mgmt. Guidance

Updated 05-09-2026bullish

Transcript signals

Bull points

  • We still know very little about 27, but we think we have the ability to navigate it just like we have in the past.
  • We're still feeling, you know, very confident about that. And as I shared in my, you know, remarks, um, we have a lot of work underway right now, um, that's AI supported. So I mentioned in some of the open marks, some of the clinical work we're doing, uh, but we believe there is a lot of opportunity across, um, our care model to really empower our providers through better information to help them avoid unnecessary specialist referrals, avoid ER visits, unnecessary services.
  • We're using AI to really understand the throughput of our centers and understand, you know, something as straightforward as the impact that cancellations have on our transportation, on our staffing.

Bear points

  • Corporate general and administrative expenses of $76.5 million increased 98.3% compared to the third quarter of fiscal year 2025, primarily driven by an increase in litigation liability.
  • as Patrick mentioned, we are beginning to see rate pressures emerge as we engage with our state Medicaid partners. While it remains early in the rate setting process, initial indications suggest rate increases in fiscal 2027 may be lower than what we have experienced historically. If this persists, and when combined with a more modest Medicare rate environment, it could create top line pressure in fiscal 2027.
Read full transcript analysis ›